Trial Profile
Real-World Comparisons of Bleeding Among Novel Oral Anticoagulant (NOAC)-Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage, Who Newly Initiated Novel Oral Anticoagulation Therapies or Were Treated With Warfarin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 Jun 2017 New trial record